Join Mergr to view all 8 acquisitions of companies in 2011, including 4 acquisitions by private equity firms, and 4 by strategics.
Enobia, which is based in Montreal and Cambridge, Mass., focuses on development of therapies for patients with genetic metabolic bone disorders. Enobia's lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs.
Enobia Pharma was acquired by Alexion Pharmaceuticals on December 28, 2011.
Join Mergr to view this profile - and discover more acquisitions of companies like Enobia Pharma.
We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.
Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.
Try us for 1 week free today!
No obligation. Cancel anytime.